CV6 Therapeutics Secures $9.2m to Progress Novel Cancer Drug to Phase 1a Trial

2022-11-02

First in Class小分子药物

Belfast, UK, 2 November 2022 – CV6 Therapeutics (‘CV6’), a drug development biotechnology company that specializes in innovative small molecule therapeutics for cancer and inflammatory diseases, announces it has secured $9.2m to progress the company’s lead oncology asset CV6-168 into a first-in-human Phase 1a clinical trial and perform further scientific development work. Investors participating in the financing include QUBIS, the commercialization arm of Queen’s University in Belfast, Invest Northern Ireland, CoFund NI, managed by Clarendon Fund Managers, Techstart Ventures as well as US and UK-based private investors. CV6 has also received a Grant for R&D from Invest Northern Ireland* to support the Phase 1a trial. CV6 is developing CV6-168, a novel, first-in-class DNA uracilation agent that selectively targets the enzyme dUTPase. Cancer cell DNA uracilation by CV6-168 is aided by combination with standard cancer therapies such as thymidylate synthase (TS) inhibitors and results in uracil-based DNA damage and cell death while simultaneously stimulating the immune system to further enhance the anticancer effect. DNA uracilation is a novel therapeutic strategy that has demonstrated effectiveness and safety in pre-clinical models with no added toxicity with drug combinations. CV6-168 is set to enter a Phase 1a clinical trial in 2023 that will focus on safety, measuring how the drug is absorbed by the body, identifying optimal dosing levels and gathering initial indications of anti-cancer activity. CV6 CEO and Founder Dr Robert Ladner said, “CV6-168 unlocks the potential of DNA uracilation as a promising new therapeutic approach to cancer treatment, with the opportunity to significantly improve outcomes for patients across multiple cancer types. Securing this financing and a grant for R&D from Invest Northern Ireland will allow us to advance CV6-168 into a first-in-human Phase 1a clinical trial, representing a key milestone for CV6.” CV6 Therapeutics is headquartered in the Patrick G. Johnston Centre for Cancer Research at Queen’s University Belfast. * Invest Northern Ireland’s R&D support is part financed by the European Regional Development Fund under the EU Investment for Growth and Jobs Programme 2014–2020. Notes to Editors About CV6 Therapeutics CV6 Therapeutics, (NI) Ltd., is a drug development biotechnology company that specializes in innovative small molecule therapeutics for cancer and inflammatory diseases. Lead oncology drug candidate CV6-168 has successfully completed all pre-clinical development milestones. The company plans to start a first-in-human phase 1a clinical trial of CV6-168 in advanced cancers in 2023. Inflammatory disease asset CV6-1271 is in preclinical-development. The company was originally founded in 2013 in Los Angeles, California and moved to Northern Ireland to establish the company at Queen’s University in 2015. For more information see our website here and LinkedIn here. Media Contacts CV6 Therapeutics Dr Robert Ladner, CEO +44 (0) 7500 444287 rladner@cv6t.com Scius Communications Katja Stout +447789435990 katja@sciuscommunications.com Daniel Gooch +447747875479 daniel@sciuscommunications.com

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构